Case Report

Early Experience of Helical Tomotherapy for Hepatobiliary Radiotherapy

Carole Massabeau, Virginie Marchand, Sofia Zefkili, Vincent Servois, François Campana, and Philippe Giraud

Department of Radiation Oncology and Medical Physics, Institut Curie, 75005 Paris, France
Department of Radiation Oncology, Institut Claudius Regaud, 31052 Toulouse, France
Department of Radiology, Institut Curie, 75005 Paris, France
Department of Radiation Oncology, European Georges Pompidou Hospital, 75015 Paris, Paris Descartes University, 75005 Paris, France

Correspondence should be addressed to Carole Massabeau, cmassabeau@hotmail.com

Received 14 April 2011; Accepted 14 May 2011

Academic Editors: A. Irisawa, C. Karaca, and B. Mauro

Copyright © 2011 Carole Massabeau et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Helical tomotherapy (HT), an image-guided, intensity-modulated, radiation therapy technique, allows for precise targeting while sparing normal tissues. We retrospectively assessed the feasibility and tolerance of the hepatobiliary HT in 9 patients. A total dose of 54 to 60 Gy was prescribed (1.8 or 2 Gy per fraction) with concurrent capecitabine for 7 patients. There were 1 hepatocarcinoma, 3 cholangiocarcinoma, 4 liver metastatic patients, and 1 pancreatic adenocarcinoma. All but one patient received previous therapies (chemotherapy, liver radiofrequency, and/or surgery). The median doses delivered to the normal liver and to the right kidney were 15.7 Gy and 4.4 Gy, respectively, below the recommended limits for all patients. Most of the treatment-related adverse events were transient and mild in severity. With a median followup of 12 months, no significant late toxicity was noted. Our results suggested that HT could be safely incorporated into the multidisciplinary treatment of hepatobiliary or pancreatic malignant disease.

1. Introduction

Majority of patients who develop either liver malignancy (metastasis or hepatobiliary primaries) have unresectable disease [1, 2]. Moreover, after first resection of liver lesions, recurrences are observed in two thirds of patients despite the use of systemic chemotherapy. In recent years, several new methods of nonsurgical ablation of liver malignancies have been tested, such as radiofrequency ablation, but also cryotherapy, laser hyperthermia, intra-arterial therapies, or ethanol injection, with variable success [3]. Until recently, radiotherapy of hepatic malignancies was playing a limited role due to the well-known limited radiotolerance of the liver [4, 5]. Recently, there is an increasing interest for modern radiotherapy as an attractive alternative, because it is noninvasive and not limited by anatomical issues associated with other therapies as the size, multiplicity and location of liver lesions [6]. New radiation techniques including intensity modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), and stereotactic radiosurgery make it possible to deliver optimally high doses to the target volume with minimal effect on adjacent radiosensitive tissues.

Literature concerned with modelling liver tolerance indicate that high doses of radiation therapy can be delivered without significant toxicity, as long as a certain amount of normal liver is spared [7, 8]. The liver parenchyma is composed of numerous functional subunits that tolerate substantial focal injury prior to any clinical sequelae. Partial liver irradiation to high doses is, consequently, possible if adequate normal liver parenchyma can be spared [9]. The risk of RT-induced liver disease (RILD) is increasing with the preexisting liver disease and with dosimetric parameters among which the most important were identified to be the mean liver dose and the volume of liver receiving more than 30 Gy [10]. With the development of new technologies and
Table 1: Patient and disease characteristics.

| Patient | Sex | Age | Performance Status (ECOG) | Primary tumour site | Previous therapies | Location/number/size of liver lesions |
|---------|-----|-----|---------------------------|--------------------|--------------------|--------------------------------------|
| 1       | M   | 51  | 0                         | Rectum Ad.         | Partial liver resection CT Pelvic RT RF | Hepatic dome 3 lesions (34; 10; 9 mm) |
| 2       | M   | 42  | 0                         | Cholangio          | Biliary stent CT    | Diffuse periductal infiltration Not measurable |
| 3       | F   | 73  | 2                         | Colon Ad.          | CT Colon surgery CT | Posterior to the right portal branch 1 lesion (20 mm) |
| 4       | F   | 60  | 0                         | Pancreatic Ad.     | CT Biliary Stent Partial liver resection CT | Pancreatic mass 1 lesion (40 mm) |
| 5       | F   | 72  | 0                         | Cholangio          | Extensive hepato-biliary surgery | Hilar region (no macroscopic disease) |
| 6       | M   | 64  | 1                         | Colon Ad.          | Colon surgery CT    | Peri-hilar metastasis 1 lesion (70 mm) |
| 7       | M   | 63  | 0                         | HepatoC.           | Left hepatectomy Partial liver resections CT | Adjacent to the hepatic vein trunk (1 lesion-36 mm) |
| 8       | F   | 80  | 0                         | Colon Ad.          | CT Partial liver resection CT | Hepatic dome 1 lesion (10 mm) |
| 9       | F   | 48  | 1                         | Cholangio          | No*                | Hilar infiltration (20 mm) |

Abbreviations: HT: helical tomotherapy; M: male; F: female; Ad: adenocarcinoma; Cholangio: cholangiocarcinoma; HepatoC: hepatocarcinoma; CT: chemotherapy; RT: radiation therapy; RF: radiofrequency ablation *The patient 9 underwent an abdominal irradiation for Hodgkin lymphoma thirty years ago.

Techniques, we are able to focus the radiation more precisely on the lesion to provide a higher dose to the tumor [11, 12]. Helical tomotherapy (HT), an image-guided, intensity-modulated radiotherapy system, can allow for simultaneous and precise targeting of multiple lesions, while sparing normal tissues [13]. The objective of the current study was to review our initial experience using HT for irradiation of hepatobiliary malignant disease.

2. Cases Presentation

2.1. Patients and Treatment. Between May 2008 and July 2010, 9 patients who underwent a course of HT (Hi-Art system, TomoTherapy, Madison, wis, USA) in the Radiation Department of the Institut Curie for malignant hepatic lesions entered in our study. The baseline characteristics of the nine enrolled patients as well as the treatment details are listed in Table 1. A total of 7 patients received chemotherapy prior to irradiation, 5 underwent previous hepatic surgery, and 2 underwent previous radiofrequency ablation. Patient 7 was a 63-year-old man whose hepatitis B-related hepatocarcinoma (Child-Pugh class A disease) was initially treated with a left lobectomy. When a multifocal recurrence occurred, both chemotherapy and two segmental liver resections were performed, leading to one year of clinical remission before another local recurrence, presented as a single 3.6 cm lesion. Since the location of this lesion (directly adjacent to the median hepatic vein) precluded surgical management and RF ablation, patient 7 was referred for the HT. Two of the 3 cholangiocarcinoma patients were treated in a curative intent in a neoadjuvant setting according to the Mayo Clinic protocol. This is a protocol combining neoadjuvant concurrent chemoradiotherapy with capecitabine and cadaver donor liver transplantation for patients with operatively confirmed stage I and II hilar cholangiocarcinoma. Concurrent capecitabine which could be used as an irradiation sensitizer, was started on the first day of irradiation, half in the morning and half in the evening, for the duration of the radiation therapy [14]. All patients provided written informed consent before HT started. HT was performed to deliver the prescribed dose in 27 or 30 daily fractions, 5 days a week. Before each treatment,
Table 2: Dosimetric constraints for each organ at risk: recommended dose-volume limits from Quantec [15] and French guidelines [16].

| Organ          | Constraint                                                                 |
|----------------|-----------------------------------------------------------------------------|
| Normal liver   | Median dose <28 Gy in (2-Gy fractions) V30 < 50%²  |
| Right kidney   | Maximum dose of 20 Gy to the total kidney Mean dose < 18 Gy² |
| Right lung     | V20 < 20%²                                                                 |
| Spinal cord    | Maximum dose of 45 Gy                                                      |

²Vx: Percentage of the organ at risk receiving more than x dose.

a megavoltage CT scan in the HT Hi-Art system was made to adjust table position and to verify the position of the tumor and vital organs.

2.2. Tomotherapy Planning. Patients were immobilized for initial simulation and for treatment with the two arms above the head in a body frame. Simulation was performed in a large bore computed tomography (CT) (Aquilion LB, Toshiba medical, Puteau, France SA) of 90 cm aperture. Images were acquired with 3-mm slice thickness from the mid-neck to the pelvis. Intravenous contrast was used to facilitate the appreciation of the tumour volume. Planning images are obtained by a four-dimensional CT (4D-CT) to assess respiratory motion. Regular breathing can lead to organ motions up to several centimeters which are taken into account by adding a specific margin around the target volume. The CT data was transferred to a linac-based planning system (Eclipse 3D version 8.1; Varian Medical Systems Inc., Palo Alto, USA) for delineating target volume and organs at risk (OAR). The gross tumour volume (GTV) was contoured manually corresponding to the tumour volume seen in the CT scan and in the co registered MRI images [17]. No specific size limit was placed on the tumor diameter. A margin of 1 cm to account for microscopic disease extension was added to the GTV to define the clinical target volume (CTV). An additional safety margin for liver movement caused by breathing and other nonspecific setup error was placed around the CTV to define the final planning target volume PTV (PTV) [18, 19]. For the OAR, the entire liver, the kidneys, the spinal cord, and the lungs were outlined. The normal liver was defined as the total liver minus the GTV. The CT images and accompanying contours were exported to the HT planning system (HIART Version 2, Tomotherapy Inc., Madison USA) for planning. According to the International Commission on Radiation Units and Measurements reports [20], the dosimetric planning objectives consisted of achieving full uniform dose coverage of the target, while keeping the dose to critical structures below their tolerance. The PTV must receive between 95% and 107% of the prescribed dose. For organs at risk (OAR), the dosimetric constraints have been set based on previously published toxicity data reviewed in the QUANTEC recommendations [21]. For partial liver irradiation, the median normal liver dose must be under 28 Gy (in 2-Gy fractions) for primary liver cancer and under 32 Gy (in 2-Gy fractions) for liver metastases. The French guidelines recommended to give less than 26 Gy in the total liver and to restrict to 50% the volume of normal liver receiving 30 Gy or more [16]. The total kidney must receive less than 20 Gy and the mean kidney dose must stay below 18 Gy; the maximum dose to the spinal cord was 45 Gy, and the percentage of the right lung receiving 20 Gy or more, must be limited to 20% (Table 2).

2.3. Dosimetric Results. The dosimetric results are listed in Table 3. The doses to the target volumes always met their prescription constraint. The median liver V30 was 12% (6–37.2), well below the 50% recommended limit, while the median liver dose was 15.7 Gy (9.7–25.9) (recommended limit: 28 Gy). The median dose delivered to the right kidney was 4.4 Gy (1.5–9.7) and remained less than the recommended constraint of 18 Gy. The same observation can be made for the lungs, the left kidney, and the spinal cord (data not shown). The distributions of isodoses for the patient 8 and 9 are shown in Figures 1 and 2.

2.4. Acute and Late Toxicities. Toxicities were assessed using the Radiation Therapy Oncology Group/National Cancer Institute Common Toxicity Criteria, version 3 morbidity scale [15], every week during the HT course to address side effects and monitor laboratory values. All but one patient completed the prescribed treatment. One of the two cholangiocarcinoma patient prematurely stopped HT for recurrent cholangitis on day 3rd of the radiation treatment, effectively treated with antibiotics, stent revision and surgery. As shown in Table 4, only minor toxicities developed during treatment. Most of the treatment-related adverse events were transient and mild in severity, with no case of direct treatment-related death. The hematologic and hepatic disorders occurred 1-2 weeks after the start of treatment and regressed spontaneously without interfering with the scheduled delivery of HT. We reported 1 thrombopenia grade 2 leading to 5 days of capecitabine interruption. The thrombopenia was most likely to be related to the capecitabine than the HT.

One patient experienced cytolyis grade 2, ten weeks after the HT course. A persistent thrombopenia grade 2 and cholestasis grade 1 (more than 4 months) occurred in one patient with progressive disease confirmed 4 months after the end of the radiation treatment. No radiation-induced liver disease was reported during the months following the HT.

2.5. Disease Outcome. After completing chemoradiotherapy, follow up was performed at 1–3 month intervals thereafter. The tumor response was assessed with follow-up CT scans. At study analysis, all but one patient, who died from progressive disease, were still alive. The median duration of followup after the HT course was 12 months (4–32). The cholangiocarcinoma patient treated in a neoadjuvant setting underwent successful cadaveric liver transplant 3 months after chemoradiotherapy with a complete histological response and remains disease-free 2 years later as the cholangiocarcinoma patient treated in an adjuvant setting. The pancreatic adenocarcinoma patient remains disease-free
Table 3: Treatment characteristics and dosimetric results.

| Patients | Radiation dose per fraction (F) | Concurrent capecitabine (mg·m²·day) | Median dose to the PTVa | PTVa volume (cc) | Normal liver volumeb (cc) | Normal liver V30c (%) | Median normal liver dose (Gy) | Median right kidney dose (Gy) |
|----------|--------------------------------|--------------------------------------|------------------------|------------------|--------------------------|-----------------------|-----------------------------|-------------------------------|
| 1        | 54 Gy 2 Gy/F                    | no                                   | 56.6                   | 417.7            | 1244                     | 8                     | 25.5                        | 1.7                           |
| 2        | 54 Gy 2 Gy/F                    | 1500                                  | 57.2                   | 381              | 1726.2                   | 37                    | 25.9                        | 5.3                           |
| 3        | 60 Gy 2 Gy/F                    | 1500                                  | 61                     | 268              | 1424.3                   | 12                    | 12.1                        | 1.5                           |
| 4d       | 54 Gy 60 Gy 2 Gy/F              | 1500                                  | 55.5e                  | 671.9            | 1653.9                   | 7.5                   | 13.2                        | 9.7                           |
| 5        | 54 Gy 1.8 Gy/F                  | 1600                                  | 54.1                   | 174.6            | 892.9                    | 17.5                  | 15.7                        | 4.4                           |
| 6        | 54 Gy 1.8 Gy/F                  | no                                   | 54                     | 262.6            | 857                      | 30                    | 22.1                        | 2.1                           |
| 7        | 60 Gy 2 Gy/F                    | no                                   | 61.1                   | 121              | 1160.1                   | 10                    | 14.3                        | 1.6                           |
| 8        | 54 Gy 2 Gy/F                    | 1500                                  | 54                      | 93.9             | 1272.3                   | 6                     | 9.7                         | 4.5                           |
| 9d       | 54 Gy 60 Gy 2 Gy/F              | 1500                                  | 54e                    | 275.9            | 1484.1                   | 37.2                  | 25.6                        | 4.5                           |

aPTV: planning target volume; bNormal liver volume: liver volume minus PTV; cV30: percentage of the normal liver receiving 30 Gy or more; dFor patient 4 and patient 9, two levels of dose were prescribed: 54 Gy to the PTV 1 (gross tumour volume (GTV) + 2 cm margin) and 60 Gy to the PTV 2 (GTV + 1 cm margin); eMedian dose to the PTV 1; fMedian dose to the PTV.

Figure 1: Distribution of isodoses with HT treatment planning in the patient 8 (hepatic dome metastasis) in axial and frontal representation. The different doses as well as the target volumes/organs at risk are represented with different colors. Red color represents the target volume dose (>54 Gy). Green color represents lower radiation doses of 30 Gy.

during 10 months then bone metastasis and local progression occurred. The hepatocellular carcinoma patient attained complete clinical remission after the helical Tomotherapy. Two years later, however, this patient experienced lung metastasis and local hepatic progression. Only one in-field progression (progression of disease inside the targeted tumor volume) occurred in the melanoma metastatic patient (patient 1), who died from his progressive disease, while the 2 colorectal metastatic patients developed exclusively out-of-field (patient 8) and distant progression without local relapse (patient 9).

3. Discussion

3.1. General and Technical Issue. Radiation oncology has seen the development of new technology which offers significant improvements in local control and reductions in toxicity. Increased doses >50 Gy with non-3D techniques improved tumor control marginally but were associated with a relatively high incidence of liver and gastrointestinal toxicity [10, 22]. Recently, the modulated intensity radiotherapy has allowed local radiation to the liver to be performed safely and have yielded promising results for dose escalation [23].
**Table 4:** Acute clinical and biological adverse events: maximum toxicity grade per patient (Radiation Therapy Oncology Group/National Cancer Institute Common Toxicity Criteria, version 3) [15].

| Patient | Nausea | Pain | Diarrhea | Fatigue | Thrombopenia | Cytolysis | Cholestasis |
|---------|--------|------|----------|---------|--------------|-----------|-------------|
| Patient 1 | 0      | 0    | 0        | 0       | 1            | 1         | 1           |
| Patient 2 | 0      | 0    | 0        | 1       | 2            | 0         | 1           |
| Patient 3 | 0      | 0    | 0        | 1       | 0            | 0         | 1           |
| Patient 4 | 0      | 0    | 0        | 0       | 0            | 0         | 0           |
| Patient 5 | 1      | 0    | 0        | 1       | 0            | 0         | 0           |
| Patient 6 | 0      | 0    | 0        | 0       | 0            | 0         | 0           |
| Patient 7 | 0      | 0    | 0        | 1       | 0            | 0         | 0           |
| Patient 8 | 0      | 0    | 0        | 1       | 1            | 0         | 0           |
| Patient 9a | 1a     | 1a   | 0        | 1a      | 0            | 1a        | 4a          |

*Symptoms were not related to the HT but most likely to biliary stent obstruction with cholangitis, which is a major concern in cholangiocarcinoma patients.*
We report here our early experience of the use of the modulated intensity with HT for irradiation of hepatobiliary malignant disease in 9 patients with several clinical settings. The HT was not limited by the tumour size, the tumour location, the multiplicity of lesions as well as a previous history of abdomen irradiation or a preexistent liver disease. Helical tomotherapy, a new type of RT, combines megavoltage computed tomography (CT) imaging with an intensity-modulated RT system. Such a combination allows for the delivery of precise RT to the tumor area while sparing normal tissues. In addition, this system can perform simultaneous RT of multiple lesions during the course of rotational fan beam RT delivery. This device is an ideal tool for delivering multifocal and high-dose radiation treatment and allows the irradiation at different dose levels in a single treatment session. With regard to radiation toxicity, in our study, treatment was feasible, safe, and very well tolerated with only mild and transient clinical or biological adverse effects. No patient developed the clinical syndrome of radiation-induced liver disease (RILD). This syndrome is known to be related to the volume of normal liver receiving more than 30 Gy [15]. By incorporating the analysis of the histogram dose volume in the treatment planning process, algorithms could allow us to better adjust the prescribed dose and regimens [24]. Data from our study indicate that the HT planning achieved to give a highly conformal treatment plan sparing as much normal liver as possible and respecting the recommended dose-volume limits, making it possible to deliver a radiation dose of 54 Gy or more, in a standard regimen (2 Gy per fraction).

3.2. HT for Liver Malignancies. Hepatocellular carcinoma (HCC) is one of the most common malignant diseases worldwide. Only 10% to 15% of patients are candidates for curative surgery because of the size of the tumour, disease multifocality, early vascular invasion, decompensated liver disease, or poor performance status [25]. Some alternative treatments, such as percutaneous ethanol injection, radiofrequency ablation, and transcatheter arterial chemoembolization, tend to be more effective in small tumours (from <2 cm to 4 cm in greatest dimension) but have some contraindications as they are invasive techniques. No standard treatment has been established in locally advanced HCC [26]. External beam irradiation therapy for HCC has been used infrequently because of the limited tolerance of the entire liver [6, 22, 27]. Case series data published by Dawson et al. [28] have shown median survivals of 11 to 15 months with the use of radiation in unresectable hepatobiliary cancer, which compares favorably with other modalities. Three-dimensional conformal and more recently IMRT has come to be recognized as a potentially option for advanced HCC, since it may enable the safe escalation of the dose to the tumor [28–31]. McIntosh et al. [32] reported initial experience with IMRT (50 Gy in 20 fractions) plus capecitabine for patients who had large HCC lesions, with acceptable toxicity and promising local control. Besides, another approach, the stereotactic body radiation therapy (SBRT) consisted of the delivery of a high tumor dose with an extreme precision in only few fractions of very high dose (10 or 20 Gy per fraction). This represents a promising noninvasive treatment for unresectable small HCC previously successfully tested in liver metastasis [33–37].

Until recently, modern radiation therapies were studied for liver metastatic patients by the way of symptom palliation [25]. The liver metastases derived most often from colorectal cancer, whose prognosis has really changed in recent years, suggests the need for an effective local treatment. The resectability rate is reported to be only 25%. The recent spread of interstitial therapies and radiofrequency has further increased the possibilities of liver metastasis treatment [3, 38, 39]. The stereotactic body radiation therapy (SBRT) has been shown to be an effective, well-tolerated treatment but the tumor size might be a limiting factor. Baisden et al. [24] proposed a model based on the planning target volume (PTV) and liver volume to predict the maximum tolerable dose (MTD) delivered to a lesion by HT-based SBRT. Exactly how high the dose should be for each treatment, how many fractions in total are optimal, and how much time should pass between treatments are still to be resolved. For metastatic liver patients with an acceptable performance status, without active systemic disease, we argue that a standard regimen (2 Gy per fraction, during 6 weeks) of the well-tolerated HT could be as interesting alternative in particular for the large and/or multiple lesions.

Intrahepatic cholangiocarcinoma (ICC) is a rare hepatic malignancy that for the 30% patients with unresectable disease is uniformly fatal [40]. Systemic chemotherapy has been disappointing in regard to its efficacy, with most regimens resulting in a median survival of 6 to 12 months [41]. There has been great interest in other modalities of treatment, particularly intra-arterial therapies, and conformal radiotherapy, such as IMRT [42–44]. Baisden et al. reported the feasibility and acceptable tolerance of photodynamic therapy and concurrent chemoradiotherapy with HT (50 Gy in 25 fractions) in 10 unresectable hilar cholangiocarcinoma [45]. The most promising results have been achieved with combinations of these techniques, with the use of neoadjuvant chemoradiotherapy prior to orthotopic liver transplantation at the Mayo Clinic [46]. This approach has provided improved histological response as well as a better outcome with a 5-year survival rate higher by 20% to 40%. The use of HT in a neoadjuvant strategy before liver transplantation might increase the tolerance of the chemoradiation course avoiding an excessive adverse event which could interfere with the liver transplantation [47].

3.3. HT for Pancreatic Malignancies. The use of HT for pancreatic adenocarcinoma, whose prognosis and local control remains a challenging issue for oncologists, has been recently introduced [48]. Indeed, Ji et al. published the early results of a feasibility study as well as the early clinical outcome of concurrent administration of capecitabine with HT in 19 patients with advanced pancreatic cancer [49]. Another basis for offering radiotherapy to patients with pancreatic cancer is palliation of symptoms due to local invasion such as biliary and gastrointestinal obstruction. Because of its
ability to restrict the dose to normal organs and minimize radiation toxicities, HT may be an ideal palliative option for challenging cases of pancreatic cancer.

3.4. Therapeutic Combinations. The use of high-precision external beam radiotherapy can be complementary or an alternative to other treatments. For example, radiation may be offered to patients with large tumors that exceed the size that can be treated by radiofrequency ablation or surgical resection. The shrinkage of these lesions could enable other local treatment. Moreover, a lesion that is treated by chemoembolization may be found to have an alternate vascular supply that cannot be occluded. Radiation can play a complementary role in these cases and be added to this modality. One study demonstrated that in HCC patients who had failed transarterial chemoembolization, local radiation induced an additional tumor response [50]. The collaboration of surgeons, medical oncologists, radiation oncologists, gastroenterologists, radiologists, and pathologists might offer better therapeutic indexes for challenging cases in a multidisciplinary approach.

4. Conclusion

We reported, here, our preliminary experience of the use of HT in various hepatobiliary malignant diseases as a way of understanding the perspectives offered by such a modern radiotherapeutic technique. Further investigations like comparative planning studies and longer followups are needed to confirm the dosimetric and clinical benefits offered by the HT over standard techniques or other new technique such dynamic arc therapy.

Conflict of Interests

No potential conflict of interests relevant to this paper was reported.

References

[1] J. M. Llovet, A. Burroughs, and J. Bruix, "Hepatocellular carcinoma: review," The Lancet, vol. 362, no. 9399, pp. 1907–1917, 2003.
[2] B. Nordlinger and P. Rougier, “Liver metastases from colorectal cancer: the turning point,” Journal of Clinical Oncology, vol. 20, no. 6, pp. 1442–1445, 2002.
[3] B. Nordlinger and P. Rougier, “Nonsurgical methods for liver metastases including cryotherapy, radiofrequency ablation, and infusional treatment: what’s new in 2001?” Current Opinion in Oncology, vol. 14, no. 4, pp. 420–423, 2002.
[4] B. Emami, J. Lyman, A. Brown et al., “Tolerance of normal tissue to therapeutic irradiation,” International Journal of Radiation Oncology Biology Physics, vol. 14, no. 1, pp. 109–122, 1991.
[5] G. B. Stillwagon, S. E. Order, C. Guse et al., “194 hepatocellular cancers treated by radiation and chemotherapy combinations: toxicity and response: a radiation therapy oncology group study,” International Journal of Radiation Oncology Biology Physics, vol. 17, no. 6, pp. 1223–1229, 1989.
[6] M. A. Hawkins and L. A. Dawson, “Radiation therapy for hepatocellular carcinoma: from palliation to cure,” Cancer, vol. 106, no. 8, pp. 1653–1663, 2006.
[7] J. C. Cheng, J. K. Wu, C. M. Huang et al., “Radiation-induced liver disease after three-dimensional conformal radiotherapy for patients with hepatocellular carcinoma: dosimetric analysis and implication,” International Journal of Radiation Oncology Biology Physics, vol. 54, no. 1, pp. 156–162, 2002.
[8] L. A. Dawson, D. Normolle, J. M. Balter, C. J. McGinn, T. S. Lawrence, and R. K. Ten Haken, “Analysis of radiation-induced liver disease using the lyman NTCP model,” International Journal of Radiation Oncology Biology Physics, vol. 53, no. 4, pp. 810–821, 2002.
[9] C. Greco, G. Catalano, A. Di Grazia, and R. Orecchia, “Radiotherapy of liver malignancies. From whole liver irradiation to stereotactic hypofractionated radiotherapy, ” Tumori, vol. 90, no. 1, pp. 73–79, 2004.
[10] J. C. Cheng, J. K. Wu, C. M. Huang et al., “Radiation-induced liver disease after radiation therapy for hepatocellular carcinoma: clinical manifestation and dosimetric description,” Radiotherapy and Oncology, vol. 63, no. 1, pp. 41–45, 2002.
[11] C. Dejean, G. Kantor, B. Henriques de Figueiredo et al., “Helical tomotherapy: description and clinical applications,” Bulletin du Cancer, vol. 97, no. 7, pp. 783–789, 2010.
[12] P. Giraud, M. Henni, and M. Housset, “Modern methods for cancer external radiation therapies,” Revue du Praticien, vol. 58, no. 15, pp. 1637–1640, 2008.
[13] J. W. Jang, C. S. Kay, C. R. You et al., “Simultaneous multtarget irradiation using helical tomotherapy for advanced hepatocellular carcinoma with multiple extrahepatic metastases,” International Journal of Radiation Oncology Biology Physics, vol. 74, no. 2, pp. 412–418, 2009.
[14] P. Das, R. A. Wolff, J. L. Abbuzzese et al., “Concurrent capecitabine and upper abdominal radiation therapy is well tolerated,” Radiation Oncology, vol. 1, article 41, 2006.
[15] C. Pan, B. Kavanagh, and L. Dawson, “Radiation-associated liver injury,” International Journal of Radiation Oncology Biology Physics, vol. 76, no. 3, supplement, pp. S94–S100, 2010.
[16] D. Azria, J. P. Gerard, G. Grehange et al., Société Française de Radiothérapie Oncologique-Guide des procédures de Radiothérapie Externe, 2007.
[17] V. S. Khoo and D. L. Joon, “New developments in MRI for target volume delineation in radiotherapy,” British Journal of Radiology, vol. 79, pp. S2–S15, 2006.
[18] G. Kantor, M. A. Mahé, P. Giraud et al., “French national evaluation for helicoidal tomotherapy: description of indications, dose constraints and set-up margins,” Cancer Radiotherapie, vol. 11, no. 6–7, pp. 331–337, 2007.
[19] K. K. Herfarth, J. Debus, F. Lohr et al., “Extracranial stereotactic radiation therapy: set-up accuracy of patients treated for liver metastases,” International Journal of Radiation Oncology Biology Physics, vol. 46, no. 2, pp. 329–335, 2000.
[20] International Commission on Radiation Units and Measurements, “Prescribing, recording and reporting photon beam delivery specifications for helical tomotherapy,” Reference for Linac Dosimetry, 2007.
[21] A. Jackson, L. B. Marks, S. M. Bentzen et al., “The lessons of QUANTEC: recommendations for reporting and gathering data on dose-volumetric dependencies of treatment outcome,” International Journal of Radiation Oncology Biology Physics, vol. 76, no. 3, supplement, pp. S155–S160, 2010.
[22] S. J. Shim, J. Seong, I. J. Lee, K. H. Han, C. Y. Chon, and S. H. Ahn, “Radiation-induced hepatic toxicity after radiotherapy
combined with chemotherapy for hepatocellular carcinoma,” 
Hepatology Research, vol. 37, no. 11, pp. 906–913, 2007.

[23] Z. G. Ren, J. D. Zhao, K. Gu et al., “Three-dimensional 
conformal radiation therapy and intensity-modulated radia-
tion therapy combined with transcatheter arterial chemoem-
bolization for locally advanced hepatocellular carcinoma: an 
irradiation dose escalation study,” International Journal of 
Radiation Oncology Biology Physics, vol. 79, no. 2, pp. 496–502, 
2011.

[24] J. M. Baisden, A. G. Reish, K. Sheng, J. M. Larner, B. D. 
Kavanagh, and P. W. Read, “Dose as a function of liver volume 
and planning target volume in helical tomotherapy, intensity-
modulated radiation therapy-based stereotactic body radia-
tion therapy for hepatic metastasis,” International Journal of 
Radiation Oncology Biology Physics, vol. 66, no. 2, pp. 620–625, 
2006.

[25] M. Sherman and J. Bruix, “Management of hepatocellular 
carcinoma,” Hepatology, vol. 42, no. 5, pp. 1208–1236, 2005.

[26] A. P. Venook, “Treatment of hepatocellular carcinoma: too 
many options?” Journal of Clinical Oncology, vol. 12, no. 6, pp. 
1323–1334, 1994.

[27] M. A. Hawkins and L. A. Dawson, “Radiation therapy for 
hepatocellular carcinoma,” Cancer, vol. 106, no. 8, pp. 1653–1663, 
2006.

[28] L. A. Dawson, C. J. McGinn, D. Normolle et al., “Escalated 
focal liver radiation and concurrent hepatic artery fluo-
roxyuridine for unresectable intrahepatic malignancies,” 
Journal of Clinical Oncology, vol. 18, no. 11, pp. 2210–2218, 
2000.

[29] J. Seong, H. C. Park, K. H. Han, and C. Y. Chon, “Clinical 
results and prognostic factors in radiotherapy for unre-
sectable hepatocellular carcinoma: a retrospective study of 158 
patients,” International Journal of Radiation Oncology Biology 
Physics, vol. 55, no. 2, pp. 329–336, 2003.

[30] K. Han, J. Seong, J. K. Kim et al., “Pilot clinical trial of localized 
concurrent chemoradiation therapy for locally advanced hep-
ato cellular carcinoma with portal vein thrombosis,” Cancer, 
vol. 115, no. 5, pp. 995–1003, 2008.

[31] E. Ben-Josef, D. Normolle, W. D. Ensminger et al., “Phase II 
trial of high-dose conformal radiation therapy with concur-
rent hepatic artery floxuridine for unresectable intrahepatic 
malignancies,” Journal of Clinical Oncology, vol. 23, no. 34, pp. 
8739–8747, 2005.

[32] A. McIntosh, K. D. Hagspiel, A. M. Al-Osaimi et al., “Accel-
erated treatment using intensity-modulated radiation therapy 
plus concurrent capecitabine for unresectable hepatocellular 
carcinoma,” Cancer, vol. 115, no. 21, pp. 5117–5125, 2009.

[33] K. K. Herfarth, J. Debus, F. Lohr et al., “Stereotactic single-
dose radiation therapy of liver tumors: results of a phase I/II 
trial,” Journal of Clinical Oncology, vol. 19, no. 1, pp. 164–170, 
2001.

[34] R. V. Tse, M. Hawkins, G. Lockwood et al., “Phase I study of 
individualized stereotactic body radiotherapy for hepatocellu-
lar carcinoma and intrahepatic cholangiocarcinoma,” Journal of 
Clinical Oncology, vol. 26, no. 4, pp. 657–664, 2008.

[35] T. E. Schefter, B. D. Kavanagh, R. D. Timmerman, H. R. 
Cardenes, A. Baron, and L. E. Gaspar, “A Phase I trial of sto-
neutic body radiation therapy (SBRT) for liver metastases,” 
International Journal of Radiation Oncology Biology Physics, 
vol. 62, no. 5, pp. 1371–1378, 2005.

[36] J. H. Kwon, S. H. Bae, J. Y. Kim et al., “Long-term effect of 
stereotactic body radiation therapy for primary hepatocellular 
carcinoma ineligible for local ablation therapy or surgical 
resection. stereotactic radiotherapy for liver cancer,” BMC 
Cancer, vol. 10, article 475, 2010.

[37] C. Louis, S. Dewas, X. Mirabel et al., “Stereotactic radio-
therapy of hepatocellular carcinoma: preliminary results,” 
Technology in Cancer Research and Treatment, vol. 9, no. 5, pp. 
479–487, 2010.

[38] W. S. Koom, J. Seong, K. H. Han, D. Y. Lee, and J. T. Lee, 
“Is local radiotherapy still valuable for patients with multiple 
intrahepatic hepatocellular carcinomas?” International Journal of 
Radiation Oncology Biology Physics, vol. 77, no. 5, pp. 1433–1440, 
2010.

[39] T. Ruers and R. P. Bleichrodt, “Treatment of liver metastases, 
an update on the possibilities and results,” European Journal of 
Cancer, vol. 38, no. 7, pp. 1023–1033, 2002.

[40] J. K. Heimbach, G. I. Gores, M. G. Haddock et al., “Liver trans-
plantation for unresectable perihilar cholangiocarcinoma,” 
Seminars in Liver Disease, vol. 24, no. 2, pp. 201–207, 2004.

[41] F. Eckel and R. M. Schmid, “Chemotherapy in advanced 
biliary tract carcinoma: a pooled analysis of clinical trials,” 
British Journal of Cancer, vol. 96, no. 6, pp. 896–902, 2007.

[42] T. A. Rich, D. B. Evans, S. A. Curley, and J. A. Ajani, “Adjuvant 
radiotherapy and chemotherapy for biliary and pancreatic 
cancer,” Annals of Oncology, vol. 5, supplement 3, pp. 75–80, 
1994.

[43] M. A. Ben-David, K. A. Griffith, E. Abu-Isa et al., “External-
beam radiotherapy for localized extrahepatic cholangiocarci-
noma,” International Journal of Radiation Oncology Biology 
Physics, vol. 66, no. 3, pp. 772–779, 2006.

[44] M. F. Gerhards, T. M. van Gulik, D. González González, 
E. A. Rauws, and D. J. Gouma, “Results of postoperative 
radiotherapy for resectable hilar cholangiocarcinoma,” World 
Journal of Surgery, vol. 27, no. 2, pp. 173–179, 2003.

[45] J. M. Baisden, M. Kahaleh, G. R. Weiss et al., “Capcetabine, 
and photodynamic therapy is feasible and well tolerated 
in patients with hilar cholangiocarcinom,” Gastrointestinal 
Cancer Research, vol. 2, no. 5, pp. 219–224, 2008.

[46] D. J. Rea, J. K. Heimbach, C. B. Rosen et al., “Liver trans-
plantation with neoadjuvant chemoradiation is more effective 
than resection for hilar cholangiocarcinom,” Annals of 
Surgery, vol. 242, no. 3, pp. 451–461, 2005.

[47] C. H. Crane, K. O. Macdonald, J. N. Vauthey et al., “Limitations 
of conventional doses of chemoradiation for unresectable biliary cancer,” International Journal of Radiation Oncology Biology Physics, vol. 53, no. 4, pp. 969–974, 2002.

[48] C. Chargari, F. Campana, P. Beuzeboc, S. Zékili, and Y. 
M. Kirova, “Preliminary experience of helical tomotherapy 
for locally advanced pancreatic cancer,” World Journal of 
Gastroenterology, vol. 15, no. 35, pp. 4444–4445, 2009.

[49] J. S. Ji, C. W. Han, J. W. Jang et al., “Helical tomotherapy 
with concurrent capcetabine for the treatment of inoperable 
pancreatic cancer,” Radiation Oncology, vol. 5, article 60, 2010.

[50] J. Seong, H. C. Park, K. H. Han et al., “Local radiotherapy 
for unresectable hepatocellular carcinoma patients who failed 
with transcatheter arterial chemoembolization,” International 
Journal of Radiation Oncology Biology Physics, vol. 47, no. 5, pp. 1331–1335, 2000.